Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136880 | 0.88 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL8741061 | 0.84 | SMN1; SMN2 (0.32) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL9136872 | 0.81 | HDAC3 (0.33) | ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC6 | |
| SCHEMBL44111 | 0.80 | HPGD (0.37) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL29361373 | 0.80 | HPGD (0.37) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL346020 | 0.79 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL30031578 | 0.79 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL321300 | 0.79 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2HDAC3HDAC6NPC1 | |
| SCHEMBL7907413 | 0.79 | NPC1 (0.34) | ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC6 | |
| SCHEMBL2283058 | 0.78 | HPGD (0.46) | ALDH1A1SMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| EP-2208737-B1 | Complement factor H-derived short consensus repeat-antibody constructs | LYSOMAB GMBH (AT) | 2017-07-05 | — | — | EP | disclosed |
| EP-2152736-B1 | COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS | LYSOMAB GMBH (AT) | 2017-07-05 | — | — | EP | disclosed |
| EP-2097529-A1 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | Osprey Pharmaceuticals USA, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090092578-A1 | Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof | OSPREY PHARMACEUTICALS USA, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008080218-A9 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | OSPREY PHARMACEUTICALS LTD (CA) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008080218-A1 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | OSPREY PHARMACEUTICALS USA, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1485500-A4 | EFFICIENT SYNTHESIS OF PROTEIN-OLIGONUCLEOTIDE CONJUGATES | BECKMAN COULTER INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1485500-A2 | EFFICIENT SYNTHESIS OF PROTEIN-OLIGONUCLEOTIDE CONJUGATES | Beckman-Coulter, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003035830-A2 | EFFICIENT SYNTHESIS OF PROTEIN-OLIGONUCLEOTIDE CONJUGATES | BECKMAN-COULTER, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6503886-B1 | Gene delivery; polypeptide conjugated to fibroblast growth factor fused to nucleic acid | SELECTIVE GENETICS, INC. | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092578-A1 | Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof | TIAL1, PTMS, LTA | ALDH1A1 4192/4885SMN1; SMN2 2689/4885HDAC3 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.